NGFR and neoplasm: RNA sequencing of CD271+ and CD271− tumor cells isolated from the same SHH MBs showed that these two cell populations are molecularly distinct; particularly, MAPK/ERK signaling pathway was upregulated in CD271+ cells and its inhibition with the MEK inhibitor selumetinib reduced CD271 expression, stem/progenitor cell proliferation, and in vivo tumorigenicity [359].